Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for Radiotherapy-Induced Thrombocytopenia in Solid Tumors
NCT07128576Phase 2Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Sep 2025
- Primary completion
- Aug 2027
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label trial of romiplostim in Thrombocytopenia (2 arms), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Proportion of patients achieving ≥50×10⁹/L increase in platelet count (PLT) from baseline within 2 weeks. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT07128576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128576.